Table 2. Basic BCVA, GLD and CRT characteristics of the included nine studies.
| Study | Combination group |
PDT group |
IVR group |
||||||
| Initial logMAR BCVA | Initial GLD (µm) | Initial CRT (µm) | Initial logMAR BCVA | Initial GLD (µm) | Initial CRT (µm) | Initial logMAR BCVA | Initial GLD (µm) | Initial CRT (µm) | |
| Koh et al 2012[22] | 0.57±0.42 | <5400 | 334.7±118.9 | 0.56±0.26 | <5400 | 285.3±105.6 | 0.72±0.32 | <5400 | 268.5±97.8 |
| Lee et al 2013 [25] | 0.46±0.30 | NR | 391.13±130.25 | 0.53±0.35 | NR | 481.33±128.46 | |||
| Oishi et al 2013 [26] | 0.57±0.31 | 3051.1±1177.7 | 366.8±113.6 | 0.48±0.27 | 3347.4±1288.3 | 418.9±168.6 | |||
| Inoue et al 2013 [27] | 0.52±0.28 | 3640±2120 | NR | 0.48±0.38 | 4171±2631 | NR | |||
| Kang and Koh 2014 [28] | 0.68±0.36 | 2810.87±974.1 | 408.01±116.51 | 0.67±0.43 | 2790.05±871.5 | 404.18±118.12 | |||
| Maruko et al 2011 [29] | 0.55±0.49 | 2905±1122 | 455±198 | 0.53±0.34 | 3013±1059 | 364±114 | |||
| Rouvas et al 2011 [30] | 0.81±0.30 | NR | 289 | 0.53±0.33 | NR | 304.36 | 0.79±0.32 | NR | 310.9 |
| Saito et al 2013 [31] | 0.52 | 4074±1459 | 385±154 | 0.58 | 4867±1855 | NR | |||
| Sakurada and Iijima 2013 [32] | 0.51±0.22 | 2039±847 | NR | 0.55±0.26 | 2364±716 | NR | |||
PDT: photodynamic therapy; IVR: Intravitreal ranibizumab; logMAR: Logarithm of minimal angle of resolution; BCVA: Best-corrected visual acuity; CRT: Central retinal thickness; GLD: Greatest linear dimension of polypoidal lesion; SD: Standard deviation; RCT: Randomized controlled trial; RS: Retrospective study; NR: Not reported.
x±s